Aspirin Professional Labeling Change Not Backed By Science – Bayer
This article was originally published in The Tan Sheet
Executive Summary
Aspirin professional labeling should not be modified to recommend a lower dosing range for secondary cardiovascular prevention, Bayer's Consumer Care Division says in recent comments to FDA